After slow rollout, Merck's Winrevair poised for 'strong uptake' in 2025: Leerink

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at Leerink Partners believe that Merck’s Winrevair “should have strong uptake growth” in 2025.